Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87


Pharmacokinetics and metabolism of 2-aminothiazoles with antiprion activity in mice.

Silber BM, Rao S, Fife KL, Gallardo-Godoy A, Renslo AR, Dalvie DK, Giles K, Freyman Y, Elepano M, Gever JR, Li Z, Jacobson MP, Huang Y, Benet LZ, Prusiner SB.

Pharm Res. 2013 Apr;30(4):932-50. doi: 10.1007/s11095-012-0912-4. Epub 2013 Feb 16.


Different 2-Aminothiazole Therapeutics Produce Distinct Patterns of Scrapie Prion Neuropathology in Mouse Brains.

Giles K, Berry DB, Condello C, Hawley RC, Gallardo-Godoy A, Bryant C, Oehler A, Elepano M, Bhardwaj S, Patel S, Silber BM, Guan S, DeArmond SJ, Renslo AR, Prusiner SB.

J Pharmacol Exp Ther. 2015 Oct;355(1):2-12. doi: 10.1124/jpet.115.224659. Epub 2015 Jul 29.


2-Aminothiazoles as therapeutic leads for prion diseases.

Gallardo-Godoy A, Gever J, Fife KL, Silber BM, Prusiner SB, Renslo AR.

J Med Chem. 2011 Feb 24;54(4):1010-21. doi: 10.1021/jm101250y. Epub 2011 Jan 19.


2-Aminothiazoles with improved pharmacotherapeutic properties for treatment of prion disease.

Li Z, Silber BM, Rao S, Gever JR, Bryant C, Gallardo-Godoy A, Dolghih E, Widjaja K, Elepano M, Jacobson MP, Prusiner SB, Renslo AR.

ChemMedChem. 2013 May;8(5):847-57. doi: 10.1002/cmdc.201300007. Epub 2013 Mar 18.


Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL.

Kamath AV, Wang J, Lee FY, Marathe PH.

Cancer Chemother Pharmacol. 2008 Mar;61(3):365-76. Epub 2007 Apr 11.


Discovery of 2-aminothiazoles as potent antiprion compounds.

Ghaemmaghami S, May BC, Renslo AR, Prusiner SB.

J Virol. 2010 Apr;84(7):3408-12. doi: 10.1128/JVI.02145-09. Epub 2009 Dec 23.


Soluble dimeric prion protein binds PrP(Sc) in vivo and antagonizes prion disease.

Meier P, Genoud N, Prinz M, Maissen M, Rülicke T, Zurbriggen A, Raeber AJ, Aguzzi A.

Cell. 2003 Apr 4;113(1):49-60.


Drug resistance confounding prion therapeutics.

Berry DB, Lu D, Geva M, Watts JC, Bhardwaj S, Oehler A, Renslo AR, DeArmond SJ, Prusiner SB, Giles K.

Proc Natl Acad Sci U S A. 2013 Oct 29;110(44):E4160-9. doi: 10.1073/pnas.1317164110. Epub 2013 Oct 15.


Influence of surface groups on poly(propylene imine) dendrimers antiprion activity.

McCarthy JM, Rasines Moreno B, Filippini D, Komber H, Maly M, Cernescu M, Brutschy B, Appelhans D, Rogers MS.

Biomacromolecules. 2013 Jan 14;14(1):27-37. doi: 10.1021/bm301165u. Epub 2012 Dec 26.


Mechanistic insights into the cure of prion disease by novel antiprion compounds.

Webb S, Lekishvili T, Loeschner C, Sellarajah S, Prelli F, Wisniewski T, Gilbert IH, Brown DR.

J Virol. 2007 Oct;81(19):10729-41. Epub 2007 Jul 25.


P-glycoprotein plays a role in the oral absorption of BMS-387032, a potent cyclin-dependent kinase 2 inhibitor, in rats.

Kamath AV, Chong S, Chang M, Marathe PH.

Cancer Chemother Pharmacol. 2005 Feb;55(2):110-6. Epub 2004 Aug 27.


Styryl-based and tricyclic compounds as potential anti-prion agents.

Chung E, Prelli F, Dealler S, Lee WS, Chang YT, Wisniewski T.

PLoS One. 2011;6(9):e24844. doi: 10.1371/journal.pone.0024844. Epub 2011 Sep 13.


Monoclonal antibodies inhibit prion replication and delay the development of prion disease.

White AR, Enever P, Tayebi M, Mushens R, Linehan J, Brandner S, Anstee D, Collinge J, Hawke S.

Nature. 2003 Mar 6;422(6927):80-3.


Biaryl amides and hydrazones as therapeutics for prion disease in transgenic mice.

Lu D, Giles K, Li Z, Rao S, Dolghih E, Gever JR, Geva M, Elepano ML, Oehler A, Bryant C, Renslo AR, Jacobson MP, Dearmond SJ, Silber BM, Prusiner SB.

J Pharmacol Exp Ther. 2013 Nov;347(2):325-38. doi: 10.1124/jpet.113.205799. Epub 2013 Aug 21.


Library synthesis and screening: 2,4-diphenylthiazoles and 2,4-diphenyloxazoles as potential novel prion disease therapeutics.

Heal W, Thompson MJ, Mutter R, Cope H, Louth JC, Chen B.

J Med Chem. 2007 Mar 22;50(6):1347-53. Epub 2007 Feb 17.


In silico studies and fluorescence binding assays of potential anti-prion compounds reveal an important binding site for prion inhibition from PrP(C) to PrP(Sc).

Pagadala NS, Perez-Pineiro R, Wishart DS, Tuszynski JA.

Eur J Med Chem. 2015 Feb 16;91:118-31. doi: 10.1016/j.ejmech.2014.07.045. Epub 2014 Jul 15.


The tyrosine kinase inhibitor STI571 induces cellular clearance of PrPSc in prion-infected cells.

Ertmer A, Gilch S, Yun SW, Flechsig E, Klebl B, Stein-Gerlach M, Klein MA, Schätzl HM.

J Biol Chem. 2004 Oct 1;279(40):41918-27. Epub 2004 Jul 9.


Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease.

Korth C, May BC, Cohen FE, Prusiner SB.

Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9836-41.


Developing Therapeutics for PrP Prion Diseases.

Giles K, Olson SH, Prusiner SB.

Cold Spring Harb Perspect Med. 2017 Apr 3;7(4). pii: a023747. doi: 10.1101/cshperspect.a023747. Review.

Supplemental Content

Support Center